DESAL-HEART: Hypertonic Saline Added to a Pre-declared Furosemide Dose in Acute Heart Failure (DESAL-HEART)
DESAL-HEART is a multicenter, randomized, open-label, blinded-endpoint, mechanistic proof-of-concept trial conducted within the Heart Failure Efficacy and Research Trial (HEART) Platform. The study will evaluate whether adding a single infusion of 3% hypertonic saline solution (HSS) to a pre-declared intravenous furosemide dose improves decongestion in patients hospitalized with acute heart failure.
調査の概要
状態
詳細な説明
Background and Rationale
Congestion is a major cause of hospitalization in patients with acute heart failure. Intravenous loop diuretics, such as furosemide, are the standard treatment for removing excess fluid, but treatment responses vary and residual congestion remains common.
Hypertonic saline may temporarily increase effective circulating blood volume, improve kidney perfusion, and enhance the delivery and effectiveness of furosemide. Although previous studies have suggested potential benefits, limitations in study quality and differences in treatment regimens have prevented definitive conclusions.
DESAL-HEART is designed to isolate the effect of hypertonic saline by ensuring that the furosemide dose is determined before randomization and administered in both treatment groups.
Study Design
A total of 60 adults hospitalized with acute heart failure and persistent congestion will be randomized in a 1:1 ratio to receive either:
A single 150 mL infusion of 3% hypertonic saline administered over 30 minutes together with a pre-declared intravenous furosemide dose; or
The same pre-declared intravenous furosemide dose alone.
Randomization will be performed centrally using REDCap, with stratification by chronic kidney disease status. The study is open-label because the control group will not receive a placebo infusion. Laboratory endpoints will be assessed objectively.
The treating clinician will determine and document the intravenous furosemide dose before randomization. Subsequent heart failure management will remain at the discretion of the treating physician.
Study Objectives and Assessments
The primary objective is to estimate the effect of hypertonic saline on NT-proBNP, a biomarker of heart failure, measured 24 ± 6 hours after randomization.
The key mechanistic secondary endpoint is spot urine sodium concentration measured 90-150 minutes after randomization, providing an early measure of the kidneys' response to diuretic treatment.
Additional assessments include:
NT-proBNP at 48 ± 6 hours after randomization.
Spot urine sodium from the first urine sample collected more than 6 hours after randomization.
Changes in body weight, hemoglobin, hematocrit, serum electrolytes, and creatinine at 24 hours.
Urine output, net fluid balance, and additional decongestive treatments during the first 24 hours.
Treatment delivery, recruitment feasibility, and completeness of outcome assessments.
Safety assessments will include infusion intolerance, clinically important electrolyte abnormalities, changes in kidney function, symptomatic hypotension, worsening respiratory status, and serious adverse events. A serum sodium increase of at least 5 mmol/L from baseline or any sodium value of at least 150 mmol/L is a prespecified adverse event of special interest.
Exploratory outcomes include major adverse kidney events and days alive and out of hospital at 30 days. Additional clinical and patient-reported outcomes will be collected through the HEART Platform.
Statistical Analysis and Study Purpose
The primary analysis will use a mixed model for repeated measures to compare log-transformed NT-proBNP at 24 and 48 hours between treatment groups, adjusting for baseline NT-proBNP, site, chronic kidney disease status, age, and sex. The treatment effect will be reported as a geometric mean ratio with a 95% confidence interval.
This 60-participant study is intended to estimate the magnitude and precision of the biological treatment effect rather than establish clinical efficacy. A prespecified Green/Yellow/Red decision framework will integrate the biological signal, urine sodium response, safety, and feasibility to determine whether further investigation in a definitive clinical outcomes trial is warranted.
研究の種類
入学 (推定)
段階
- フェーズ 4
連絡先と場所
研究連絡先
- 名前：Justin Ezekowitz, MD
- 電話番号：780-492-0712
- メール：jae2@ualberta.ca
研究連絡先のバックアップ
- 名前：Fernando G Zampieri, MD,PhD
- 電話番号：587-588-6151
- メール：fzampier@ualberta.ca
研究場所
-
-
Alberta
-
Edmonton、Alberta、カナダ
- University of Alberta
-
コンタクト：
- Fernando G Zampieri, MD, PhD
- 電話番号：587-588-6151
- メール：fzampier@ualberta.ca
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Adults aged 18 years or older.
-
Primary diagnosis of acute heart failure with dyspnea and at least two of the following signs of congestion:
- Pulmonary congestion on chest radiograph.
- Rales on chest auscultation.
- Clinically relevant peripheral edema.
- Elevated jugular venous pressure.
-
Randomization within 24 hours of the hospital admission order or admitted status, with admission to a hospital ward or intensive care unit, including patients remaining in the emergency department awaiting transfer.
-
Persistent congestion with a clinical plan for another intravenous furosemide dose.
-
NT-proBNP ≥1000 pg/mL, regardless of the presence of atrial fibrillation.
-
Estimated glomerular filtration rate (eGFR) >15 mL/min/1.73 m².
-
Serum sodium ≥125 mmol/L and <145 mmol/L.
-
Meets the eligibility requirements of the HEART Platform Master Protocol.
Exclusion Criteria:
- Hypertonic saline already administered during the current presentation.
- A clinical indication for therapeutic hypertonic saline.
- Contraindication to either study treatment, including known allergy, hypersensitivity, or intolerance to hypertonic saline or furosemide.
- Requirement for mechanical circulatory support.
- Dialysis-dependent kidney failure or anuria (absence of urine production).
- Treating physician's judgment that either treatment strategy is inappropriate, or any condition that, in the opinion of the investigator, would make participation unsafe or interfere with interpretation of study results.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Hypertonic Saline Plus Furosemide
Participants will receive a single 150 mL intravenous infusion of 3% hypertonic saline over 30 minutes, administered concurrently with a pre-declared intravenous furosemide dose. The furosemide dose will be determined by the treating clinician before randomization. Subsequent treatment will follow standard clinical care. |
A single 150 mL intravenous infusion of 3% sodium chloride (hypertonic saline solution) administered over 30 minutes, initiated at the same time as the pre-declared intravenous furosemide dose. A single intravenous dose of furosemide determined and documented by the treating clinician before randomization. The same pre-declared dosing approach applies to both treatment groups. Subsequent diuretic treatment is determined by the treating physician according to standard clinical care. |
|
アクティブコンパレータ：Furosemide Alone
Participants will receive a pre-declared intravenous furosemide dose without hypertonic saline. The furosemide dose will be determined by the treating clinician before randomization using the same dosing approach as the intervention group. Subsequent treatment will follow standard clinical care. |
A single intravenous dose of furosemide determined and documented by the treating clinician before randomization. The same pre-declared dosing approach applies to both treatment groups. Subsequent diuretic treatment is determined by the treating physician according to standard clinical care. |
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change From Baseline in NT-proBNP at 24 Hours
時間枠：Baseline to 24 hours after randomization
|
Change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) from baseline to 24 hours after randomization. NT-proBNP is a blood biomarker of heart failure. |
Baseline to 24 hours after randomization
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Spot Urine Sodium Concentration at 90-150 Minutes
時間枠：90-150 minutes after randomization
|
Spot urine sodium concentration measured 90-150 minutes after randomization to assess the early natriuretic response to intravenous furosemide with or without hypertonic saline. |
90-150 minutes after randomization
|
|
Change From Baseline in NT-proBNP at 48 Hours
時間枠：Baseline to 48 hours after randomization
|
Change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) from baseline to 48 hours after randomization to assess the persistence of the treatment effect on this heart failure biomarker |
Baseline to 48 hours after randomization
|
|
Spot Urine Sodium Concentration at 6 Hours
時間枠：First urine void more than 6 hours after randomization
|
Spot urine sodium concentration measured from the first urine sample collected more than 6 hours after randomization to assess the sustained natriuretic response to treatment. The actual sample collection time will be recorded. |
First urine void more than 6 hours after randomization
|
|
Change From Baseline in Hemoglobin at 24 Hours
時間枠：Baseline and 24 hours after randomization
|
Change in blood hemoglobin concentration from baseline to 24 hours after randomization, measured using routine complete blood count testing. |
Baseline and 24 hours after randomization
|
|
Change From Baseline in Hematocrit at 24 Hours
時間枠：Baseline and 24 hours after randomization
|
Change in hematocrit from baseline to 24 hours after randomization, measured using routine complete blood count testing |
Baseline and 24 hours after randomization
|
|
Change From Baseline in Body Weight at 24 Hours
時間枠：Baseline and 24 hours after randomization
|
Change in body weight from baseline to 24 hours after randomization to assess fluid removal and decongestion. |
Baseline and 24 hours after randomization
|
|
Total Urine Output Through 24 Hours
時間枠：Randomization through 24 hours
|
Total recorded urine output during the first 24 hours after randomization to assess the diuretic response to treatment. |
Randomization through 24 hours
|
|
Net Fluid Balance Through 24 Hours
時間枠：Randomization through 24 hours
|
Net fluid balance, calculated as total recorded fluid intake minus total recorded fluid output during the first 24 hours after randomization. |
Randomization through 24 hours
|
|
Total Furosemide-Equivalent Dose Through 24 Hours
時間枠：Randomization through 24 hours
|
Total furosemide-equivalent diuretic dose administered during the first 24 hours after randomization, including the pre-declared study dose and subsequent diuretic treatments. |
Randomization through 24 hours
|
|
Other Decongestive Therapies Through 24 Hours
時間枠：Randomization through 24 hours
|
Use of additional decongestive therapies during the first 24 hours after randomization, including treatments administered at the discretion of the treating physician. |
Randomization through 24 hours
|
|
Change From Baseline in Serum Sodium
時間枠：Baseline and 24 hours
|
Change in serum sodium concentration from baseline to 24 hours after randomization. |
Baseline and 24 hours
|
|
Change From Baseline in Serum Chloride
時間枠：Baseline and 24 hours
|
Change in serum chloride concentration from baseline to 24 hours after randomization. |
Baseline and 24 hours
|
|
Change From Baseline in Serum Potassium
時間枠：Baseline and 24 hours
|
Change in serum potassium concentration from baseline to 24 hours after randomization. |
Baseline and 24 hours
|
|
Change From Baseline in Serum Bicarbonate
時間枠：Baseline and 24 hours
|
Change in serum bicarbonate concentration from baseline to 24 hours after randomization. |
Baseline and 24 hours
|
|
Change From Baseline in Serum Creatinine
時間枠：Baseline and 24 hours
|
Change in serum creatinine concentration from baseline to 24 hours after randomization to assess kidney function. |
Baseline and 24 hours
|
協力者と研究者
出版物と役立つリンク
便利なリンク
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- DESAL-01
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。